



ASX ANNOUNCEMENT

13 November 2015

Exalt Resources settles oversubscribed public offer

*MedAdvisor to list on the ASX via Exalt Resources (ASX:ERD)
Readmission to the ASX to be announced imminently*

MELBOURNE, 13 November 2015: Exalt Resources Limited (ASX:ERD; to be renamed MedAdvisor Limited ASX:MDR) (**Company**), has settled its heavily oversubscribed public offer. The Company is now awaiting notification from the ASX of its date of readmission and commencement of trading.

Last month, Exalt successfully raised \$5 million via a public offer of shares managed by Corporate Advisor Peloton Capital, in connection with its acquisition of MedAdvisor International Pty Ltd (**MedAdvisor**), an Australian medical technology business focused on designing and commercialising world class software platforms for medication management.

The Company also announces changes to its Board of Directors with effect from 12 November 2015:

- Mr Robert Read (CEO), Mr Josh Swinnerton (CTO) and Mr Jim Xenos (non-executive director) have been appointed as Directors;
- Mr Peter Dykes and Mr Stephen Brockhurst have resigned as Directors; and
- Mr Carlo Campiciano has been appointed as joint Company Secretary.

-ENDS-

About MedAdvisor

MedAdvisor is an Australian software systems developer focused on addressing gaps in personal medication adherence. MedAdvisor's free app connects to pharmacy dispensing systems to automatically retrieve medication records and drive an intelligent training, information and reminder system to ensure correct and reliable medication use. It was the most downloaded pharmacy or medication-related app in Apple and Android stores in Australia in 2014 and 2015, and is being used by more than 93,000 Australians. A quarter of all Australian pharmacies subscribe to the MedAdvisor software platform.

MedAdvisor has established sales and marketing partnerships with private health insurer, BUPA, and has training and service contracts with top tier global pharmaceutical companies, including GSK, AstraZeneca, UCB and Apotex.



For more information

Robert Read
MedAdvisor
Tel: +61 3 9095 3036
robertr@medadvisor.com.au

Catie Corcoran
Buchan Consulting
Tel: +61 2 9237 2807
ccorcoran@buchanwe.com.au

Peter Bennetto
Exalt Resources Ltd
Tel: +61 8 9481 0389
info@exaltresources.com.au

Nicholas Downes
Peloton Capital
Tel: +61 2 8651 7802
nicholas.downes@pelotoncapital.com.au

For personal use only